Q3 EPS Estimates for Guardant Health Decreased by Analyst

Guardant Health, Inc. (NASDAQ:GH - Free Report) - Investment analysts at Leerink Partnrs reduced their Q3 2025 earnings per share estimates for Guardant Health in a report released on Monday, April 21st. Leerink Partnrs analyst P. Souda now expects that the company will earn ($0.76) per share for the quarter, down from their previous estimate of ($0.75). The consensus estimate for Guardant Health's current full-year earnings is ($2.90) per share. Leerink Partnrs also issued estimates for Guardant Health's Q4 2026 earnings at ($0.70) EPS and FY2027 earnings at ($2.13) EPS.

Guardant Health (NASDAQ:GH - Get Free Report) last announced its quarterly earnings data on Thursday, February 20th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.15). Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. The business had revenue of $201.81 million during the quarter, compared to analyst estimates of $192.50 million.

Several other equities analysts have also weighed in on the stock. Canaccord Genuity Group upped their price objective on shares of Guardant Health from $42.00 to $60.00 and gave the company a "buy" rating in a report on Monday, February 24th. Stephens reiterated an "overweight" rating and issued a $55.00 price target on shares of Guardant Health in a report on Wednesday, March 26th. Barclays reduced their price objective on Guardant Health from $60.00 to $55.00 and set an "overweight" rating for the company in a research note on Thursday, April 10th. Piper Sandler increased their target price on Guardant Health from $34.00 to $50.00 and gave the stock an "overweight" rating in a report on Wednesday, February 26th. Finally, Stifel Nicolaus boosted their price target on shares of Guardant Health from $45.00 to $53.00 and gave the company a "buy" rating in a research note on Friday, February 21st. Twenty investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $49.00.

Guardant Health Stock Up 2.8 %

Guardant Health stock opened at $43.80 on Wednesday. The company has a market capitalization of $5.41 billion, a PE ratio of -12.30 and a beta of 1.45. Guardant Health has a 12-month low of $16.77 and a 12-month high of $50.89. The firm's fifty day moving average is $43.43 and its 200 day moving average is $36.76.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. R Squared Ltd bought a new stake in Guardant Health during the 4th quarter valued at $26,000. SBI Securities Co. Ltd. purchased a new stake in Guardant Health during the fourth quarter valued at about $43,000. Kimelman & Baird LLC bought a new stake in Guardant Health during the fourth quarter worth about $58,000. NewEdge Advisors LLC lifted its stake in Guardant Health by 13.5% during the fourth quarter. NewEdge Advisors LLC now owns 1,929 shares of the company's stock worth $59,000 after purchasing an additional 230 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Guardant Health in the 4th quarter worth about $61,000. 92.60% of the stock is owned by institutional investors.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.